Status:
COMPLETED
Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza
Lead Sponsor:
Materia Medica Holding
Conditions:
Influenza
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is: * to assess the efficacy of Ergoferon in treatment of influenza; * to assess the safety of Ergoferon in treatment of influenza; * to compare the efficacy of Ergoferon an...
Detailed Description
The overall duration of a patient participation in the trial is 6 days (screening/randomization/therapy onset - day 1; study therapy period - day 1-5; follow-up period - day 6).
Eligibility Criteria
Inclusion
- Patients aged 18 to 70 years.
- Patients who were admitted to hospital within 48 hours from the onset of influenza signs.
- Patients with body temperature ≥37,8°C when visiting a doctor + severity of influenza symptoms ≥4 scores (presence of at least 1 non-specific flu symptom ≥2 scores and 1 nasal/ throat/ chest symptom ≥ 2 scores or greater number of symptoms with the severity ≥1 score).
- Diagnosed influenza confirmed by rapid diagnostic test (OSOM Influenza A\&B Test).
- The possibility to start therapy within 48 hours after the onset of the first symptoms of influenza.
- Usage of contraceptive methods by both gender patients of reproductive age during the trial and within 30 days after ending the participation in the trial.
- Availability of signed patient information sheet (Informed Consent form) for participation in the clinical trial.
Exclusion
- Suspected pneumonia, bacterial infection or the presence of a severe disease requiring usage of antibacterial drugs (including sulphanilamides) starting from Day 1 of the disease.
- Severe influenza with indications for hospitalization.
- Suspected early manifestations of diseases that have symptoms similar to influenza symptoms (other acute respiratory and infectious diseases, influenza-like syndrome at the onset of systemic connective tissue disorders, hematologic neoplasms and other pathology).
- Patients requiring concurrent antiviral products forbidden by the study.
- Medical history of primary and secondary immunodeficiencies. а) lymphoid immunodeficiencies (Т-cell and/or В-cell, immunodeficiencies with predominant antibody deficit); b) phagocytic deficits; c) complement factor deficit; d) combined immunodeficiencies including AIDS secondary to HIV infection; toxic, autoimmune, infectious, radiation panleukopenic syndrome; total lymphocytopenic syndrome; polyclonal lymphocyte activation syndrome; postsplenectomic syndrome; congenital asplenia; abnormal immune complex syndrome associated with infectious, autoimmune and allergic diseases.
- Medical history of sarcoidosis
- An oncological disease/suspected oncological disease.
- Exacerbated or decompensated chronic diseases affecting a patient's ability to participate in the clinical trial.
- Medical history of polyvalent allergy.
- Allergy/intolerance to any of the components of the product used for influenza therapy.
- Impaired glucose tolerance, type 1 and type 2 diabetes mellitus.
- Malabsorption syndrome, including congenital or acquired lactose deficiency or another disaccharide deficiency.
- Pregnancy, breast-feeding.
- Consumption of narcotics, alcohol \> 2 alcohol units per day, mental diseases.
- Use of any medicine listed in the section "Prohibited concomitant treatment" within 30 days preceding the inclusion in this study.
- Patients who, from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the regimen of the study drugs.
- Participation in other clinical studies within 1 month prior to enrollment in the current trial.
- Patients related to the research staff of the clinical trial site who are directly involved in the trial or are the immediate family member of the researcher. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.
- Patients employed with OOO "NPF "MATERIA MEDICA HOLDING" (i.e., the company's employee, part-time employee under contract, or appointed official in charge of the trial, or their immediate family).
Key Trial Info
Start Date :
February 20 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 16 2018
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT01850446
Start Date
February 20 2015
End Date
April 16 2018
Last Update
April 16 2020
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
The Non-State Health Care Institution "Road Hospital of the Open Joint Stock Company" Russian Railways"
Chelyabinsk, Russia, 454091
2
The State Budgetary Educational Institution of Higher Professional Education " Kazan State University of Medicine" Ministry of Health of the Russian Federation
Kazan', Russia, 420012
3
Pirogov Russian National Research Medical University
Moscow, Russia, 117997
4
Federal State Budgetary Military Educational Institution of Higher Professional Education "Military-Medicine Academy named after S. M. Kirov" of Ministry of Defence of Russian Federation
Saint Petersburg, Russia, 194044